

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

03 Jul 2026

### Bioequivalence study of Gabapentin 300 mg Capsule (Teb Mofid Nikan) versus Neurontin 300 mg (Pfizer) Capsule after single oral dosing in healthy volunteers

#### Protocol summary

##### Study aim

Bioequivalence study of Gabapentin 300 mg Capsule (Teb Mofid Nikan) versus Neurontin 300 mg (Pfizer) Capsule after single oral dosing in healthy volunteers

##### Design

Bioequivalence study, with control group, double-blind, randomized, on 24 volunteers, from each volunteer 17 blood samples were taken. Sealed envelope is used for randomization.

##### Settings and conduct

The subject of this biopharmaceutical and pharmacokinetic study is the location of Tehran Shimi Company located in Tehran. The study was blinded to the study participants by removing the drugs from the original package and placing the test and reference drugs in the same package, and the participants were not aware of the type of drug they were taking. The crossover design is such that Iranian medicine will be prescribed to the first group in the first week and to the second group in the second week. Brand medicine will be prescribed to the second group in the first week and to the first group in the second week.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: general health (liver, heart and kidneys), body mass index (18-28), informed consent, age (50-18) Exclusion criteria: smoking, history of cardiovascular disease, history of liver disease and Renal, alcohol and drug addiction, history of allergy to Gabapentin

##### Intervention groups

Intervention group: Receives one Capsule of test drug (Gabapentin 300 mg Capsule Teb Mofid Nikan). Blood samples were taken from the volunteers for 24 hours at the mentioned times after drug administration and the drug concentration in plasma samples was measured by liquid chromatography with UV detector. Control group: Receives one reference medicine Capsule (Neurontin 300

mg Pfizer Pharmaceutical Company), and the test is implemented like the Intervention group

##### Main outcome variables

Determination of blood concentration profile parity of brand drug with generics

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20220111053692N5**

Registration date: **2022-11-11, 1401/08/20**

Registration timing: **registered\_while\_recruiting**

Last update: **2022-11-11, 1401/08/20**

Update count: **0**

##### Registration date

2022-11-11, 1401/08/20

##### Registrant information

##### Name

Bardia Jamali

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 8897 4707

##### Email address

info@tampouya.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2022-09-11, 1401/06/20

##### Expected recruitment end date

2022-12-11, 1401/09/20

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Bioequivalence study of Gabapentin 300 mg Capsule (Teb Mofid Nikan) versus Neurontin 300 mg (Pfizer) Capsule after single oral dosing in healthy volunteers

**Public title**

Bioequivalence study of Gabapentin 300 mg Capsule

**Purpose**

Other

**Inclusion/Exclusion criteria****Inclusion criteria:**

18 to 55 years old Weight in range of 10 % proper body weight All volunteers should be in a good health condition on the basis of medical history, physical examination, routine blood test. and possessing negative test for hepatitis B surface antigen (HBs-Ag), antihepatitis-C antibody (anti-HCV), and anti-HIV. just man

**Exclusion criteria:**

Volunteers with hypersensitivity to Gabapentin were excluded. those with known history of drug abuse. alcohol consumer or cigarette smokers. Taking medications that have drug interactions with Gabapentin until one month before studying. disinclination to take the test Blood donation or blood loss of more than 200 ml in the past month

**Age**

From **18 years** old to **55 years** old

**Gender**

Male

**Phase**

Bioequivalence

**Groups that have been masked**

- Participant
- Care provider

**Sample size**

Target sample size: **24**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

In order to randomly allocate people in two groups, 24 cards with numbers 1 to 24 will be used in closed envelopes that are placed in random order. After entering the study, each candidate will take an envelope, numbers 1-12 will be in group A and numbers 13-24 will be in group B. Group A will receive intervention 1 (test product) and group B will receive intervention 2 (reference product) and after the first period, the interventions of the two groups will be moved for the second period.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

This study is a Double-blind (participant) clinical trial.

Gabapentin and Neurontin tablets are removed from the package by the administrator and placed in similar and coded cans.

**Placebo**

Not used

**Assignment**

Crossover

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Research Ethics Committees of The Institute of Pharmaceutical Sciences -Tehran University of Medical

**Street address**

Research Institute of Pharmaceutical Sciences, second floor of the old building, Faculty of Pharmacy, Enqelab Square, 16 Azar St.

**City**

Tehran

**Province**

Tehran

**Postal code**

1417613151

**Approval date**

2022-09-19, 1401/06/28

**Ethics committee reference number**

IR.TUMS.TIPS.REC.1401.052

**Health conditions studied****1****Description of health condition studied**

Bioequivalence study of Gabapentin 300 mg Capsule (Teb Mofid Nikan) versus Neurontin 300 mg (Pfizer) Capsule after single oral dosing in healthy volunteers

**ICD-10 code****ICD-10 code description****Primary outcomes****1****Description**

Drug concentration in plasma samples

**Timepoint**

In times 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 30 Hours after the start of the intervention

**Method of measurement**

chromatography

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: Receives one Capsule of test drug (Gabapentin 300 mg Capsule Teb Mofid Nikan). Blood samples were taken from the volunteers for 24 hours at the mentioned times after drug administration and the drug concentration in plasma samples was measured by liquid chromatography with UV detector.

#### Category

Other

### 2

#### Description

Control group: Receives one reference medicine Capsule (Neurontin 300 mg Pfizer Pharmaceutical Company). Blood samples were taken from the volunteers for 24 hours at the mentioned times after drug administration and the drug concentration in plasma samples was measured by liquid chromatography with UV detector

#### Category

Other

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Tehran Chemie Pharmaceuticals Company

##### Full name of responsible person

Bardia Jamali

##### Street address

Navard Ave, 17 Shahrivar St, 5th Km of Fat`h Highway,

##### City

Tehran

##### Province

Tehran

##### Postal code

1378756411

##### Phone

+98 21 6107 4387

##### Fax

+98 21 6107 4070

##### Email

info@tampouya.com

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Teb Mofid Nikan Pharmaceutical Company

#### Full name of responsible person

Dr.Mohammad Reza Zargarzadeh

#### Street address

6th floor, Shafayab Building, Beheshti Street, No. 275

#### City

Tehran

#### Province

Tehran

#### Postal code

3361658369

#### Phone

+98 21 8817 5765

#### Fax

+98 26 4422 8116

#### Email

info@mofidpharma.com

#### Web page address

https://www.mofidpharma.com

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

No

#### Title of funding source

Teb Mofid Nikan Pharmaceutical Company

#### Proportion provided by this source

100

#### Public or private sector

Private

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Other

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Tam Pouya Consulting & Research Company

##### Full name of responsible person

Bardia Jamali

##### Position

manager

##### Latest degree

Ph.D.

##### Other areas of specialty/work

Medical Pharmacy

##### Street address

Unit 1, No. 1, Crot Building, Jahan mehr Street, Shahid Gomnam Street, Fatemi Square

##### City

Tehran

##### Province

Tehran

##### Postal code

1431653941

##### Phone

+98 21 8897 4707

##### Fax

+98 21 8897 4707

**Email**

info@tampouya.com

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Tam Pouya Consulting & Research Company

**Full name of responsible person**

Bardia Jamali

**Position**

manager

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Unit 1, No. 1, Crot Building, Jahan mehr Street, Shahid Gomonam Street, Fatemi Square

**City**

Tehran

**Province**

Tehran

**Postal code**

1431653941

**Phone**

+98 21 8897 4707

**Fax**

+98 21 8897 4707

**Email**

info@tampouya.com

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Tam Pouya Consulting & Research Company

**Full name of responsible person**

Motahareh Moafi

**Position**

Office worker

**Latest degree**

Bachelor

**Other areas of specialty/work**

Office worker

**Street address**

Unit 1, No. 1, Crot Building, Jahan mehr Street, Shahid Gomonam Street, Fatemi Square

**City**

Tehran

**Province**

Tehran

**Postal code**

1431653941

**Phone**

+98 21 8897 4707

**Fax**

+98 21 8897 4707

**Email**

info@tampouya.com

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

No more information

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available